Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





IRON OXIDE FUME								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 1309-37-1; CHEMICAL FORMULA: Fe2O3
OSHA formerly had an 8-hour TWA limit of 10 mg/m3 for iron oxide fume. The ACGIH has established a limit of 5 mg/m3, measured as iron, total particulate. The proposed PEL was 5 mg/m3, and NIOSH (Ex. 8-47, Table N1) supported the proposed limit. However, the final rule retains OSHA’s former limit of 10 mg/m3 for this substance. The fume of iron oxide is red-brown in color.
Animals exposed to iron oxide or to iron oxide mixed with less than 5 percent silica by inhalation or by intratracheal injection did not develop pulmonary fibrosis (Naeslund 1940/Ex. 1-650; Harding, Grout, Durkan et al. 1950, as cited in ACGIH 1986/Ex. 1-3, p. 325). Inhalation of iron oxide dust also did not produce lung cancer in mice (Muller and Erhardt 1956/Ex. 1-648).
The evidence of iron oxide’s toxicity in humans is conflicting. Drinker, Warren, and Page (1935/Ex. 1-315) concluded that exposures to iron oxide fume should be maintained below 10 mg/m3, and a U.S. Department of Labor study (1941, as cited in ACGIH 1986/Ex. 1-3, p. 325) found that exposures below 30 mg/m3 were without adverse effect. There are several studies, on the other hand, that report chest X-ray abnormalities in miners, welders, silver polishers, electrolytic iron oxide workers, foundry workers, and boiler scalers (Doig and McLaughlin 1936/Ex. 1-626; Stewart and Faulds 1934/Ex. 1-764; Doig and McLaughlin 1948/Ex. 1-627; McLaughlin, Grout, Barrie, and Harding 1945/Ex. 1-642; Davidson 1951, as cited in McLaughlin 1951/Ex. 1-727; Pendergrass and Leopold 1945/Ex. 1-653; Dunner and Hermon 1944/Ex. 1-731) exposed to iron oxide dust or fume. Some of these workers developed disabling pneumoconiosis; however, the exposures of many of these workers were mixed and in some cases included exposure to varying amounts of silica.
McLaughlin (1951/Ex. 1-727), whose opinion on the subject is widely accepted, believes that the presence of iron oxide dust or fume in the lung causes a pigmentation (termed siderosis) that is responsible for the changes seen in exposed individuals’ chest X-rays. Siderosis is believed not to progress to fibrosis, and 6 to 10 years of exposure to about 15 mg/m3 iron oxide dust is required before this condition develops (Fawcett 1943/Ex. 1-736; Fleischer, Nelson, and Drinker 1945/Ex. 1-1051; Hamlin and Weber 1950/Ex. 1-698). However, no studies are available that correlate exposure levels with X-ray changes. Dr. Stuart M. Brooks (NIOSH 1986b, p. 425) notes that “[m]ore sophisticated physiologic testing, including measurement of the lung’s mechanical properties, is required to better document lung function changes that may occur following inhalation of iron-containing dusts. In vitro studies or animal experimentation might be helpful in determining dose-response relationships, understanding lung clearance mechanisms for iron, and elucidating any fibrogenic properties of various ferrous compounds.”
Some studies have shown that workers with exposures to iron oxide and such other substances as silica, radon gas, diesel exhaust, corn oils, and the thermal decomposition products of synthetic resins (Faulds 1957/Ex. 1-635; Dreyfus 1936/ Ex. 1-897; Bidstrup 1959/Ex. 1-1030; Boyd, Doll, Faulds, and Leiper 1970/Ex. 1-716; Braun, Guillerm, Pierson, and Sadoul 1960/Ex. 1-1141; Monlibert and Roubille 1960/Ex. 1-647; Jorgensen 1973/Ex. 1-1023; Muller and Erhardt 1956/Ex. 1-648; Koskela, Hernberg, Karava et al. 1976/Ex. 1-744; Gibson, Martin, and Lockington 1977/Ex. 1-1053) have a greater risk of developing lung cancer. However, OSHA agrees with the ACGIH that, “at this time, it is not generally accepted that exposure to iron oxide dust or fume causes cancer in man” (ACGIH 1986/ Ex. 1-3, p. 325). Stokinger (1984/Ex. 1-672) concluded that exposure to iron oxide dust and fume per se was not carcinogenic.
Several industry commenters (Exs. 8-22, 3-349, 3-829, 129, and 188; Tr. XI, pp. 137-138) objected to the proposed reduction in the PEL for iron oxide on the grounds that exposure to this substance does not cause fibrosis or pulmonary impairment, but rather siderosis, which is a benign pneumoconiosis. The American Iron and Steel Institute (Ex. 129, pp. 12-13) described siderosis as “simply a description of a condition that appears on radiographs.” OSHA disagrees with Mr. Hernandez’ assessment of the health effects potentially associated with exposure to iron oxide because the Agency believes that any occupational exposure that causes foreign substance to lodge in body tissues is undesirable. However, the Agency concurs with NIOSH’s Dr. Brooks (NIOSH 1986b, p. 425) that additional research is necessary to determine why the lung is unable to clear iron-containing dusts after inhalation.
Accordingly, OSHA finds it appropriate to retain the Agency’s former PEL for iron oxide dust and fume of 10 mg/m3, measured as total particulate. The Agency concludes, based on the evidence currently available, that this limit will protect workers from developing of siderosis, a benign pneumoconiosis that occurs after many years of exposure to levels of iron oxide dust or fume in excess of 15 mg/m3, and accumulation of iron dust in the lungs associated with ferric oxide exposure.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue